GameStop Plummets, BioNTech to Buy CureVac, Oracle Soars
Jun 12, 2025
GameStop experiences a sharp decline in stock price as it pivots towards trading cards, with plans to issue $1.75 billion in convertible bonds. Meanwhile, BioNTech announces a $1.25 billion acquisition of CureVac, boosting its oncology focus, while CureVac's shares soar. On a brighter note, Oracle's shares hit record highs after projecting impressive growth in cloud infrastructure sales, showcasing its ambitions in the competitive cloud computing landscape.
05:31
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
GameStop's Trading Card Focus
GameStop is focusing on its trading card business, fitting its heritage and core customer base.
The company plans to issue $1.75 billion in convertible bonds, which worried investors, dropping the stock by up to 25%.
insights INSIGHT
BioNTech Acquires CureVac for Oncology
BioNTech is acquiring CureVac for about $1.25 billion to boost its oncology business.
CureVac shareholders benefit with a 34% premium and will own 4%-6% of BioNTech after the deal closes.
insights INSIGHT
Oracle's Cloud Surge and AI Drive
Oracle shares soared on a 70% projected gain in cloud infrastructure sales this year.
Strategic partnerships with OpenAI, Amazon, and Meta boost Oracle’s AI and cloud ambitions significantly.
Get the Snipd Podcast app to discover more snips from this episode
- GameStop (GME) shares plummeted today. The company had two developments. First, GameStop is focused on growing its trading card business. That is according to CEO Ryan Cohen. The business of Pokémon and sports trading cards “is in line with our heritage,” Cohen said. “It fits our trade-in model, it appeals to our core customer base and it’s deeply embedded in physical retail.” The second development is GameStop plans to offer $1.75 billion worth of convertible bonds, which would make the video-game retailer one of the year’s biggest issuers of the equity-linked securities.
- BioNTech (BNTX) agreed to buy former Covid vaccine rival CureVac NV (CVAC) for about $1.25 billion in an all-stock transaction that will boost its growing oncology business. CureVac investors will get approximately $5.46 in BioNTech shares for each CureVac one, the companies said Thursday. The price represents a 34% premium to CureVac’s closing share price on Wednesday. CureVac shareholders will own between 4% and 6% of BioNTech once the deal closes. Shares of BioNTech are flat while CureVac shares surged.
- Oracle (ORCL) shares soared to a record high after the software maker projected a 70% gain in cloud infrastructure sales this fiscal year, giving a bullish outlook for the closely watched business. The company, long known for its database software, has been gaining traction in its effort to become a major player in the business of cloud computing — renting out computing power and storage — by targeting clients focused on artificial intelligence work. Earlier this year, it announced a joint venture dubbed Stargate to provide OpenAI with massive sums of computing power.
Stock Movers